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Background: The glycated haemoglobin A1c (HbA1c) level may be used for screening for type 2 diabetes and
prediabetes instead of a more burdensome oral glucose tolerance test (OGTT). However, among the high-risk South
Asian population, little is known about the overlap of the methods or about the metabolic profiles of those
disconcordantly diagnosed.
Methods: We included 944 South Asians (18–60 years old), whom we screened with the HbA1c level and the
OGTT in The Hague, the Netherlands. We calculated the area under the receiver-operator characteristic curve
(AUROC) with a 95% confidence interval of HbA1c using the American Diabetes Association classifications, and
determined the sensitivity and specificity with 95% confidence intervals at different thresholds. Moreover, we
studied differences in metabolic characteristics between those identified by HbA1c and by the OGTT alone.
Results: The overlap between HbA1c and OGTT classifications was partial, both for diabetes and prediabetes.
The AUROC of HbA1c for OGTT defined diabetes was 0.86 (0.79–0.93). The sensitivity was 0.46 (0.29–0.63); the
specificity 0.98 (0.98–0.99). For prediabetes, the AUROC was 0.73 (0.69–0.77). Each of the 31 individuals with diabetes
and 353 with prediabetes identified with the HbA1c level had a high body mass index, large waist circumference,
high blood pressure, and low insulin sensitivity, all of which were similar to the values shown by those among the 19
with diabetes or 62 with prediabetes who only met the OGTT criteria, but not the HbA1c criteria.
Conclusions: The HbA1c level identified a partially different group than the OGTT did. However, both those
identified with the HbA1c level and those identified with the OGTT alone were at increased metabolic risk.
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Populations of South Asian origin living in industrialised
countries are known to be at high risk of type 2 diabetes
and cardiovascular diseases. Thus they form an impor-
tant target group for active screening and prevention in
clinical practice [1-4]. A recent study has shown that
such an initiative can potentially provide a substantial
benefit in reducing cardiovascular risk [4].
The effectiveness of screening, however, depends in
part on the ability of the test method to identify the
population at risk. Until recently, the oral glucose toler-
ance test (OGTT) was recommended for diagnosing
diabetes and for detecting individuals at high risk of de-
veloping diabetes. In 2010, the American Diabetes Asso-
ciation updated its recommendations to include glycated
haemoglobin A1c (HbA1c) at the level of 6.5% or more
(≥48 mmol/mol) as a diagnostic option for non-pregnant
adults [5]. Because the HbA1c level can be determined
with a single blood sample, it has practical advantages
and is less burdensome than the OGTT for screening
purposes [5]. Further, a number of studies have screened
various ethnic populations [6-10]. Most of these studies
report that screening based on the HbA1c level may lead
to the identification of fewer new cases of diabetes and
prediabetes than screening with the OGTT. In this case,
there is only a partial overlap [6-10]. Screening with the
Hb1Ac level misses some cases that would be detected
with the OGTT. Although studies from India suggest that
a similar pattern may be expected, such evidence is lack-
ing for South Asians living in industrialised countries
[10-12]. This is relevant because the overlap between the
HbA1c method and other methods may vary across ethnic
groups and across different contexts [6]. Moreover, one
recent study shows that the HbA1c levels and OGTT
fasting and 2-h glucose levels were higher among South
Asians in the UK than among Europeans [13].
A discordance may occur because of measurement
variability or because the HbA1c level and the OGTT
hallmark different physiological processes [5]. This im-
plies that the metabolic profiles of individuals discor-
dantly diagnosed may differ. Thus, their future health
risks may also differ. Indeed, studies among European-
origin populations and one study in India have shown
that the metabolic profiles differed between those identi-
fied with the HbA1c level and those identified with the
OGTT only [13-15]. Therefore, among the high-risk
South Asian populations living in industrialised countries,
it is important to note the characteristics of the metabolic
profiles of those who were and those who were not identi-
fied with the HbA1c level. The latter group would have
been identified with the OGTT.
We evaluated the overlap between classifications and
the sensitivity and specificity of HbA1c for diagnosing
OGTT-defined diabetes and prediabetes (consideringimpaired fasting glucose and/or impaired glucose tole-
rance). The 18 to 60-year-old Hindustani Surinamese par-
ticipants were screened via family practices in The Hague,
the Netherlands. Furthermore, we compared the metabolic
profiles of individuals who were HbA1c-identified with the
metabolic profile of those whom the OGTT could have
identified, but were not HbA1c-identified.Methods
Study design and population
We analysed the data for 944 18 to 60-year-old Hindustani
Surinamese participants in a screening program for the
DHIAAN study, a culturally targeted, lifestyle-intervention
trial. We use the term Hindustani Surinamese to refer
to people with South Asian ancestral origin who migrated
to the Netherlands via Suriname and their offspring.
The Hindustani Surinamese are the descendants of the
indentured labourers from North India – Uttar Pradesh,
Uttaranchal, and West Bihar – between 1873 and 1917.
The two large migration waves, around 1975 and 1980, of
Hindustani Surinamese to the Netherlands were caused
mainly by the political situation in Suriname [16].
The methods of the study have been described else-
where [17]. In brief, potential participants were selected
from 48 family physician lists in The Hague by means of
name analysis. All who were not already known to have
diabetes received an invitation followed by a written re-
minder and up to five contact attempts by telephone.
Volunteers could also make an appointment for the
screening. The participation rate was 21.8% (Figure 1).
Because oral glucose tolerance was only tested between
18 May 2009 and 19 April 2010, we only used data for
those participating during this period (n = 968). Partici-
pants who had not completed the OGTT or whose
HbA1c measurement was missing were excluded, leaving
944 participants (Figure 1).
The Institutional Review Board of the Academic Medical
Centre of the University of Amsterdam approved the
study. All participants provided written informed consent.Data collection
Participants completed a brief questionnaire about demo-
graphics (e.g. country of birth), known risk factors (e.g.
family history) and cardiovascular health. Furthermore, a
physical examination was carried out. Weight was re-
corded to the nearest 500 g. Height and waist circumfer-
ence were measured to the nearest 0.01 m. We calculated
the body mass index (BMI; kg/m2) from the weight and
height. Blood pressure was measured with the participant
in the seated position (OmronM5-1, Omron, Hoofddorp,
the Netherlands). A maximum of five measurements were
taken. We calculated the mean from the first two mea-
surements with less than 5 mmHg difference.
Excluded (n = 7714; 72.9%): 
Did not meet the screening inclusion criteria (n = 1658 ; 
21.5%) 
Actively declined to participate (n = 1804; 23.4%) 
Other reasons (n = 49; 0.6%) 
Analysed (n = 944; 97.5%) 
Excluded (n = 24; 2.5%): 
No 2-h postload plasma glucose (n = 10; 41.7%) 
No HbA1c value (n = 14; 58.3%)
People screened between May 2009 and April 2010 (n = 968; 42.0%)* 
People screened (n = 2307; 21.8%. Net participation 25.8%) 
Excluded (n = 562; 5.3%) 
No show (n = 298; 53.0 %) 
Not reached (n = 264; 47.0%)
People who made appointment for screening (n = 2869; 27.1%. Net response 32.1%) 
Assessed for eligibility (n = 10,583) 
 Selected via  family physicians’ registers (n = 10,420) 
 Volunteers (n = 163)
Figure 1 Flow diagram from eligibility assessment to inclusion in analyses. Legend: * All participants underwent an oral glucose tolerance
test (OGTT) between 18 May 2009 and 19 April 2010. Oral glucose tolerance was no longer tested after April 2010.
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sample and to undergo an OGTT (the glucose load was
75 g). We analysed the following elements:
1. Fasting plasma glucose. We used the hexokinase
method. The samples were collected in BD
Vacutainers Fluoride/EDTA Tubes, centrifuged and
analysed on a Roche Modular Analytics P (Roche
Diagnostics Nederland, Almere, The Netherlands)
on the same day.
2. HbA1c. We used high-performance liquid
chromatography (DCCT aligned) and analysed the
samples on a Tosoh G7 analyser (Tosoh Europe BV,
Amsterdam, The Netherlands), and Menarini HA-
8160 (A. Menarini Diagnostics Benelux NV,
Valkenswaard, The Netherlands) on the day of
collection. The variation coefficients were 84 mmol/
mol ± 2.0% and 33 mmol/mol ± 2.0%. The Hb
variants HbS, HbD, and HbC were automatically
reported. HbE and HbJ were verified manually.
3. Insulin. We used the sandwich immunoassay,
analysed on a Roche Modular Analytics E170 P
(Roche Diagnostics Nederland, Almere, The
Netherlands).
Furthermore, a 2-h standard 75-g OGTT was per-
formed. We used the HOMA Calculator (University of
Oxford) [18] to determine the insulin sensitivity [in %;homeostasis model assessment (HOMA)-s] and beta cell
function (in %; HOMA-b) from fasting plasma glucose
and insulin levels (pmol/l).
We used American Diabetes Association recommenda-
tions to classify prediabetes and diabetes [5,19]. We de-
fined the criteria for diagnosing diabetes on the basis of
the OGTT as a fasting plasma glucose value of 126 mg/dl
(7.0 mmol/l) or more and/or a 2-h postload glucose value
of 200 mg/dl (11.1 mmol/l). We defined the criteria for
diagnosing prediabetes as a fasting plasma glucose value
of 100–125 mg/dl (5.6–6.9 mmol/l) and/or a 2-h postload
glucose value of 140–199 mg/dl (7.8–11.1 mmol/l) [5,19].
Furthermore, the criterion for diagnosing of diabetes
on the basis of the Hb1Ac level was a value of 6.5%
(48 mmol/mol) or more, and for prediabetes, an HbA1c
level of 5.7%-6.5% (39–48 mmol/mol).
Statistical analysis
First, we described the population characteristics with
medians plus interquartile ranges or percentages. We also
calculated the prevalence of diabetes and prediabetes. We
determined the overlap between the classifications for dia-
betes and prediabetes, which we defined as the number of
cases identified with both the HbA1c level and the OGTT
divided by all cases identified with the HbA1c level.
Second, we calculated the area under the receiver-
operator characteristic curve (AUROC) and the 95%
confidence intervals for HbA1c to identify OGTT-
Table 1 Background characteristics and prevalences of
type 2 diabetes and prediabetes
Total study population
N= 944
Age in years 43.9 (35.6–51.0)
Number of men (%) 372 (39.4)




University or equivalentc 141 (14.9)
Family with diabetes (%)d 690 (73.1)
BMI in kg/m2 25.7 (23.1–28.4)
Overweight: 23≥ BMI < 27.5 kg/m2 (%) 410 (43.4)
Obesity: ≥ 27.5 kg/m2 (%) 304 (32.2)
Waist circumference in cm 87.7 (80.7–95.3)
Number with hypertension (%)e 295 (31.3)
Systolic blood pressure in mmHg 125 (114–138)
Diastolic blood pressure in mmHg 80 (73–88)
Plasma glucose in mmol/l
Fasting 4.9 (4.6–5.4)
2 h 5.3 (4.4–6.6)
HbA1c
in mmol/mol 38 (34–40)
in % 5.6 (5.3–5.8)
Insulin in pmol/l 73.6 (50.0–104.9)
HOMA–S in %f 72.1 (51.6–105.3)
HOMA–B in %f 118.7 (92.7–152.3)
OGTT-defined type 2 diabetes (%)g 35 (3.7)
OGTT-defined prediabetes (%)h 191 (20.2)
HbA1c-defined type 2 diabetes (%)i 31 (3.3)
HbA1c-defined prediabetes (%)j 366 (38.8)
Data are presented as medians (interquartile range) or n (percentages).
aPrimary education or less.
bLow vocational training, lower secondary education, intermediate vocational
training and higher secondary education.
cHigher vocational training or university.
dFirst and second grade.
e Systolic blood pressure≥ 140 mmHg and/or of distolic blood pressure≥ 90 mmHg
or if hypertension medication;
fHOMA-S and HOMA-b were determined from fasting plasma glucose and
insulin levels (pmol/l) with the HOMA Calculator (University of Oxford) [16].
gOGTT diagnosis of type 2 diabetes: fasting plasma glucose ≥ 126 mg/dl
(7.0 mmol/l) and/or 2-h plasma glucose ≥ 200 mg/dl (11.1 mmol/l).
hOGTT diagnosis of prediabetes: fasting glucose value of 100–125 mg/dl
(5.6 – 6.9 mmol/l) and/or a 2-h postload glucose value of 140–199 mg/dl
(7.8–11.1 mmol/l).
iHbA1c diagnosis of type 2 diabetes: HbA1c ≥ 6.5% (≥ 48 mmol/mol).
jHbA1c diagnosis of prediabetes: 5.7% ≤ HbA1c < 6.5%
(39 ≤ HbA1c < 48 mmol/mol).
BMI, body mass index; HbA1c, glycated haemoglobin A1c; HOMA, homeostasis
model assessments; OGTT, oral glucose tolerance test.
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the basis of the local recommendations at the time the
study was initiated. We identified the optimal HbA1c
threshold for diabetes by interpolating from the AUROC;
we selected the point that maximised sensitivity and specifi-
city by inspecting the cross-tabulations of the sensitivity
and specificity. We then calculated the sensitivity, specifi-
city, and positive predictive value (PPV) for HbA1c at the
recommended and optimal thresholds, with 95% confidence
intervals based on bootstrap methods using 2000 samples
[20]. After excluding participants with diabetes, we did the
same for prediabetes.
Third, we compared those with prediabetes or diabetes
according to the recommended thresholds for HbA1c
with individuals who only met the recommended OGTT
(but not HbA1c) criteria. For this, we used Kruskal-
Wallis tests and Mann–Whitney U tests. For reference,
we also presented the characteristics of participants
whom we could not classify with any of the tests. After
excluding all participants with diabetes according to ei-
ther the HbA1c level or the OGTT, we did the same for
prediabetes. We used SPSS 18.0 (Chicago, Illinois) and
R2.10.1 (R Foundation for Statistical Computing, 2009)
for the statistical analyses.
Results
The median age of our study population was 43.9 years,
39.4% were male, and 14.5% were born in the Netherlands
(Table 1). The prevalences of diabetes based on the OGTT
and the HbA1c level were 3.7% (n = 35) and 3.3% (n = 31),
respectively. The prevalence of prediabetes based on the
OGTT was 20.2% (n = 191), whereas with the HbA1c
method, the prevalence of diabetes was 38.8% (n = 366).
Overall, the overlap for diabetes and prediabetes was par-
tial: 51.6% of the participants with diabetes based on the
HbA1c level of 6.5% or more also fulfilled the criteria for
diabetes based on plasma glucose. For prediabetes, this
was 54.2%. The overlap for HbA1c with impaired fasting
glucose (43.0%) was higher than the overlap with impaired
glucose tolerance (25.6%).
The AUROC for HbA1c as a predictor of OGTT-defined
diabetes was 0.86 (0.79–0.93). At the recommended
threshold (≥ 6.5%), the sensitivity of HbA1c as a predictor
of OGTT-defined diabetes was 0.46 (0.29–0.63); the speci-
ficity, 0.98 (0.98–0.99); and the PPV 0.52 (0.35–0.69). The
optimal HbA1c threshold for diabetes was 6.3% (45 mmol/
mol). At this threshold we found a sensitivity of 0.63
(0.49–0.77), a specificity of 0.96 (0.95–0.97), and a PPV of
0.37 (0.25–0.49). The AUROC for prediabetes was 0.73
(0.69–0.77). At the recommended HbA1c threshold as a
predictor of OGTT-defined prediabetes, the sensitivity,
specificity, and PPV were 0.66 (0.59–0.73), 0.68 (0.64–
0.71), and 0.35 (0.30–0.40), respectively. The optimal range
for HbA1c for predicting prediabetes was 5.8–6.3% (40–45
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city of 0.78 (0.75–0.81), and a PPV of 0.41 (0.35–0.47).
As expected, individuals not diagnosed with diabetes or
prediabetes had better metabolic profiles with lower blood
pressures, lower BMIs, smaller waist circumferences, and
higher median HOMA-s and HOMA-b than those diag-
nosed as having diabetes or prediabetes (p < 0.05 for all
characteristics; Table 2). We did not find statistically sig-
nificant differences between those with diabetes based on
the HbA1c level and those who would have been identified
solely with the OGTT, apart from differences in fasting
plasma glucose and postload plasma glucose (Table 2).Table 2 Differences in characteristics according to diagnosis o
glucose tolerance test and the haemoglobin A1c level
Type 2 diabetes Nondiabetic HbA
(OGGT-/Hba1c-) n= 894 (Hb
FPG in mmol/l a 4.9 (4.6–5.3) 6.7
2 hour PG in mmol/l a 5.2 (4.4–6.3) 9.2
HbA1c in %a 5.6 (5.3–5.8) 6.8
HbA1c in mmol/mol a 38 (34–40) 51 (
Age in years 43.4 (35.0–50.3) 46.0
Male 350 (39.1) 12 (
BMI in kg/m2 25.5 (23.0–28.2) 28.6
Waist circumference in cm 87.2 (80.3–95.0) 97.2
Systolic blood pressure in mmHg 124 (114–136) 134
Diastolic blood pressure in mmHg 80 (73–88) 86 (
Insulin in pmol/l 70.8 (47.9–100.7) 120
HOMA-s in %b 75.4 (53.5–108.7) 44.5
HOMA-b in %b 119.3 (93.2–152.0) 112
Prediabetesc Non-pre-diabetic HbA
(OGTT-/HbA1c-), n= 479 HbA
FPG in mmol/l*a 4.8 (4.5–5.0) 5.2
2 hour PG in mmol/l a 4.9 (4.2–5.8) 5.9
HbA1c in %a 5.4 (5.2–5.5) 5.9
HbA1c in mmol/mol a 35 (33–37) 41 (
Age in years 40.1 (31.1–47.1) 48.1
Male in % 163 (34.0) 154
BMI in kg/m2 24.7 (22.2–27.3) 26.5
Waist circumference in cm 83.7 (77.2–91.0) 90.5
Systolic blood pressure in mmHg 120 (110–131) 128
Diastolic blood pressure in mmHg 77 (71–84) 82 (
Insulin in pmol/l 67.4 (45.1–95.1) 79.1
HOMA-s in %b 79.2 (57.9–117.5) 67.2
HOMA-b in %b 122.3 (96.2–156.0) 113
Data are presented as medians (interquartile range) or n (percentages).
aVariables on which the classification of prediabetes and type 2 diabetes was based
bHOMA-s and HOMA-b were determined from FPG and insulin levels (pmol/l) with
cAll participants with type 2 diabetes according to either HbA1c or OGTT were excl
BMI, body mass index; FPG, fasting plasma glucose; HbA1c, glycated haemoglobin AThose diagnosed with prediabetes with the HbA1c level
did not differ from those meeting only the oral glucose
tolerance criteria, apart from differences in HbA1c, fasting
plasma glucose, and postload plasma glucose. Neverthe-
less, those diagnosed with both the HbA1c level and the
OGTT had worse metabolic profiles than those identified
with the HbA1c level alone (Additional file 1).
Discussion
We found that we identified fewer new cases of diabetes
when we used the HbA1c method, but more new cases
of prediabetes than we did when we used the OGTT inf type 2 diabetes and prediabetes based on the oral
1c OGTT only p-value for HbA1c
vs. OGTT onlyA1c+) n = 31 (OGTT+/HbA1c-) n= 19
(5.5–7.4) 5.7 (5.3–6.5) <0.05
(5.9–12.8) 12.0 (11.4–12.4) <0.05
(6.6–7.1) 5.9 (5.6–6.3) 0.06
49–54) 41 (38–45) 0.06
(38.3–56.3) 48.7 (43.1–52.3) 0.43
38.7) 10 (52.6) 0.72
(25.4–29.9) 27.9 (24.8–30.0) 0.68
(90.0–102.3) 92.0 (88.3–100.0) 0.35
(117–144) 125 (118–143) 0.67
82–96) 82 (74–94) 0.20
.1 (75.0–190.0) 128.5 (90.6–195.0) 0.63
(28.2–67.9) 40.7 (27.2–59.0) 0.67
.5 (70.9–138.5) 122.9 (91.5–180.3) 0.17
1c OGTT only p-value
1c +) n = 353 (OGTT+/HbA1c-) n= 62
(4.9–5.6) 5.6 (4.9–5.8) <0.05
(4.8–7.2) 7.0 (5.4–8.2) <0.05
(5.7–6.0) 5.4 (5.2–5.6) <0.05
39–42) 36 (33–38) <0.05
(41.3–53.4) 46.0 (39.4–52.1) 0.19
(43.6) 32 (51.6) 0.06
(24.1–29.6) 26.5 (23.4–29.3) 0.74
(84.9–99.1) 92.2 (84.7–99.6) 0.66
(118–142) 129 (117–137) 0.61
76–90) 81 (75–88) 0.26
(54.2–116) 79.9 (62.5–116.5) 0.54
(46.7–98.4) 65.6 (45.4–83.1) 0.47
(81.1–151.2) 112.7 (85.5–138.3) 0.43
.
the HOMA Calculator (University of Oxford) [16].
uded from the analyses for prediabetes.
1c; OGTT, oral glucose tolerance test; PG, plasma glucose.
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overlap of the classifications based on the HbA1c level
and the OGTT was only partial, and the sensitivity and
specificity (prediabetes only) of HbA1c for identifying
OGTT-defined diabetes and prediabetes were low. Re-
gardless of the partial overlap, we found that all those
identified had poor metabolic profiles. The metabolic
profiles of those identified with the HbA1c level and
those identified with the OGTT alone did not differ.
This was the case for both diabetes and prediabetes.
Although the AUROC in our study was high, the low
sensitivity of HbA1c for OGTT-defined diabetes and
prediabetes was in line with previous studies in various
ethnic groups [8,10,11,21-23]. For instance, a recent cost
analysis in a South Asian population aged 40–75 years
in the UK reports low sensitivity of HbA1c (at >6.5%)
for diabetes [23]. Although many studies have reported a
relatively high specificity, a study in India – similarly to
our study – found low specificity of HbA1c, particularly
for prediabetes [8,10,11,21-23]. The lower optimal
HbA1c threshold for prediabetes in our population was
in line with the threshold that the Indian study recom-
mended [10]. Moreover, the lower optimal HbA1c thresh-
old corresponds to the American Diabetes Association’s
current recommendations [19]. Yet, the continued low
sensitivity and specificity for this lower threshold seems to
support the World Health Organisation’s recommendation
not to use HbA1c to determine prediabetes [24].
Data characterising participants discordantly categorised
with the HbA1c level and the OGTT in South Asian popu-
lations in industrialised countries is lacking. One study in
India suggests that, as they did in our study, the use of A1c
criteria would identify a different set of individuals with
milder glucose intolerance [12]. This Indian study has also
found lower serum triglyceride levels among those diag-
nosed with the HbA1c level [12]. Previous studies in other
populations have been inconsistent. Our results appear to
be in line with some studies reporting that those diagnosed
with the HbA1c level had as unfavourable metabolic pro-
files as those identified with the OGTT [15,25]. However,
in contrast to our results, Boronat et al. report that indivi-
duals newly diagnosed with diabetes who meet the HbA1c
criteria for diabetes have higher BMIs, higher HOMA insu-
lin resistance, and lower HDL (high density lipoprotein)
cholesterol than individuals fulfilling the OGTT criteria
only [14]. The difference between the Indian study and
ours is likely related to differences in the overlap of the
measurements associated with the ethnic background of
the study population or the setting in which the study
took place.
Notably, we found that all individuals identified should
be considered at risk of adverse outcomes, regardless of
the criterion used [26-28]. For instance, those identified
in our study with the HbA1c level or with the OGTTalone all had relatively high BMIs and waist circumfe-
rences. This is particularly important for those with pre-
diabetes. Previous studies have shown that South Asians
develop complications of obesity, such as diabetes, at
lower thresholds for BMI and waist circumferences than
individuals of European origin [29,30]. To identify all in-
dividuals at risk of adverse outcomes, a strategy that
combines more than one diagnostic method should per-
haps be considered for this population instead of the
strategy of choosing between the HbA1c level and the
OGTT. However, this should also depend on the associ-
ation of either criterion with the occurrence of compli-
cations. A combined testing strategy may not be feasible
or acceptable in the local context, e.g. because of budget
restrictions.
Limitations
Our study has a few limitations that merit discussion.
The first one is the relatively low participation rate, even
though it is higher than the participation rate in two re-
cent studies among populations of South Asian origin
selected from general practices in the UK [4,31]. This
may be related to the recruitment strategy in our study,
which was more intensive than the strategies of the UK
studies. Our results may have been affected if the par-
ticipation was selective. We did find evidence for a rela-
tively lower response rate among men and younger
participants. However, this is not likely to have greatly
influenced our results: previous studies have not consis-
tently found differences in the relationship between
HbA1c- and OGTT-diagnosed diabetes when the cha-
racteristics sex and age have been correlated [32,33].
The second limitation of our study is the relatively low
prevalence of newly diagnosed diabetes, which may have
influenced the power of the analyses. Therefore, a lack
of significant differences between individuals with OGTT-
and HbA1c-diagnosed diabetes may reflect a true lack of
difference, but may also be the result of lack of power to
demonstrate actual differences. In addition, the small
number of individuals diagnosed implies that no adjust-
ment could be made for relevant parameters, such as sex
and age, in the comparisons of characteristics. The low
prevalence may partly be a result of the intensified case
finding recommended for this population in the guideline
of the Dutch College of General Practitioners [34]. Given
that this guideline is based on fasting plasma glucose, the
recommended case finding might have also affected the
reported overlap of the classifications based on the HbA1c
level and the OGTT.
Finally, we might not have measured all the relevant
metabolic parameters. For instance, other studies have
found differences in HDL [14,15]. In contrast to other stu-
dies, we could not take lipid profiles into account because
they were not measured during the initial screening.
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Classifications of diabetes and prediabetes with the HbA1c
level and the OGTT only partially overlapped among the
18 to 60-year-old South Asian population in our study.
Importantly, both those identified with the HbA1c level
and those identified with the OGTT alone had adverse
metabolic profiles. These two groups form an important
target group for preventive interventions to reduce their
future health risks. This implies that it may be worthwhile
to consider a strategy in which these diagnostic methods
are combined for South Asian populations. Therefore, if it
proves feasible in the local context, we recommend that
future studies evaluate the efficiency of different diagnos-
tic strategies for the uptake, the number of identifiable
cases, and potential gains in terms of averted health risks.
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Title of data: Differences in characteristics according to diagnosis of type
2 diabetes and prediabetes based on OGTT and HbA1c. Description of
data: In this file we report on the metabolic characteristics of those
diagnosed with the HbA1c level and the OGTT versus those diagnosed
with the HbA1c level alone or with the OGTT alone.
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